BioSpace News Archive

Precision Optics Corporation, Inc. announced that it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 420,000 shares of the Company’s common stock pursuant to a private placement, resulting in gross proceeds of approximately $2.52 million before deducting placement agent commissions and other estimated offering expenses.

CUTERA, INC. a global leader in aesthetic and dermatology solutions, announces a new U.S. Food and Drug Administration Clearance of AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris.

Jaguar Health, Inc. announced that at 6 p.m. EDT on Wednesday, June 21, 2023, Lisa Conte, Jaguar’s president, founder, and CEO, will present virtually at the MedInvest Oncology Investor Conference and will be available to participate in virtual one-on-one meetings during the event.

Relievant Medsystems announced the publication of three-year pooled results from two prospective clinical trials that further validate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.

SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, announced the launch of simonONE directly to patients to provide affordable, fast, non-invasive whole body MRI screening.

IntegriChain and Knipper Health announced a non-exclusive joint initiative to support emerging manufacturers launching new products that need comprehensive 3PL services, order-to-cash, government pricing, and claims adjudication support.

Breast Cancer Canada announced a new research grant in collaboration with AstraZeneca Canada, a global, science-led biopharmaceutical company and Illumina, a global leader in DNA sequencing and array-based technologies.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora”) and Sentrx Animal Care (“Sentrx”) announced today they have amended their existing licensing agreement for patents and technology related to Kiora’s KIO-201 product candidate

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the “Company”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)

PharmaCyte Biotech, Inc. announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest.